Life sciences employer
Vividion Therapeutics
2 open positions
- Active openings
- 2
- US-based roles
- 0
- Remote-friendly
- 0
- Last updated
- 2026-09-05
What Vividion Therapeutics is hiring for
Open positions
3 active- Principal Scientist, Chemical DevelopmentSep 10
- Senior Scientist / Principal Scientist / Associate Director, BiotransformationSep 5
- Senior Research Associate, Pharmacology (Contractor)Aug 21
About Vividion Therapeutics
Claim to unlockMission, culture, and benefits - visible once this page is claimed and verified.
Updates
Vividion Therapeutics Doses First Patient in Phase Ib Combination Study of WRN Inhibitor VVD-214 in Patients with Advanced Colorectal Cancer
Jun 23, 2026
Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers
Jan 6, 2026
Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry
Jan 6, 2026
Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology
Dec 22, 2025
A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth
Dec 22, 2025
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
Oct 9, 2025